A new meta-analysis suggests that zinc supplementation could improve some metabolic parameters in patients with gestational diabetes, for example, reduce fasting plasma glucose (FPG), insulin and homeostatic model assessment of insulin resistance (HOMA-IR) and increase quantitative insulin-sensitivity check index (QUICKI). The findings were published in the Journal of Maternal-Fetal & Neonatal Medicine.
Researchers performed a meta-analysis of five randomised controlled trials (n=263) identified through the PubMed, Embase and Cochrane Central Register of Controlled Trials databases. Primary outcome was FPG, and secondary outcomes included insulin levels, HOMA-IR, QUICKI, low-density lipoprotein (LDL) cholesterol and total cholesterol.
Compared with the control group for gestational diabetes, zinc supplementation was associated with a significant reduction in FPG (standard mean differences [SMD], −0.52; 95% CI, −0.82 to −0.21; P=.0008). Zinc supplementation was also associated with reductions in insulin (SMD, −0.68; 95% CI, −0.98 to −0.37; P<.0001 and homa-ir ci to p an increase in quicki compared with the control intervention. zinc supplementation had no substantial effect on ldl cholesterol total cholesterol.>
According to the authors, this meta-analysis strengthens the findings of previous studies, suggesting "zinc supplementation has valuable anti-inflammatory effects, which may provide important benefits to metabolic status of gestational diabetes."